vs
ICU MEDICAL INC（ICUI）与PROG Holdings, Inc.（PRG）财务数据对比。点击上方公司名可切换其他公司
PROG Holdings, Inc.的季度营收约是ICU MEDICAL INC的1.2倍（$651.6M vs $540.7M），PROG Holdings, Inc.净利率更高（5.5% vs -2.9%，领先8.4%），PROG Holdings, Inc.同比增速更快（457.1% vs -14.1%），过去两年PROG Holdings, Inc.的营收复合增速更高（4.9% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
PROG Holdings是一家总部位于美国的金融科技企业，主要面向美国本土市场提供灵活的租购及销售点融资解决方案，核心业务涵盖零售合作伙伴融资、消费信贷与支付服务，帮助消费者无需满足传统信用要求即可购买电子产品、家居用品等商品。
ICUI vs PRG — 直观对比
营收规模更大
PRG
是对方的1.2倍
$540.7M
营收增速更快
PRG
高出471.3%
-14.1%
净利率更高
PRG
高出8.4%
-2.9%
两年增速更快
PRG
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $651.6M |
| 净利润 | $-15.7M | $36.1M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 10.0% |
| 净利率 | -2.9% | 5.5% |
| 营收同比 | -14.1% | 457.1% |
| 净利润同比 | 34.0% | 3.8% |
| 每股收益（稀释后） | $-0.63 | $3.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIPRG
| Q1 26 | — | $651.6M | ||
| Q4 25 | $540.7M | $525.4M | ||
| Q3 25 | $537.0M | $595.1M | ||
| Q2 25 | $548.9M | $604.7M | ||
| Q1 25 | $604.7M | $684.1M | ||
| Q4 24 | $629.8M | $558.9M | ||
| Q3 24 | $589.1M | $606.1M | ||
| Q2 24 | $596.5M | $592.2M |
净利润ICUIPRG
| Q1 26 | — | $36.1M | ||
| Q4 25 | $-15.7M | $40.5M | ||
| Q3 25 | $-3.4M | $33.1M | ||
| Q2 25 | $35.3M | $38.5M | ||
| Q1 25 | $-15.5M | $34.7M | ||
| Q4 24 | $-23.8M | $57.5M | ||
| Q3 24 | $-33.0M | $84.0M | ||
| Q2 24 | $-21.4M | $33.8M |
毛利率ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUIPRG
| Q1 26 | — | 10.0% | ||
| Q4 25 | 1.0% | 6.9% | ||
| Q3 25 | 2.6% | 9.0% | ||
| Q2 25 | 1.9% | 10.0% | ||
| Q1 25 | 2.1% | 8.2% | ||
| Q4 24 | 6.0% | 8.9% | ||
| Q3 24 | 1.4% | 8.1% | ||
| Q2 24 | 1.3% | 9.4% |
净利率ICUIPRG
| Q1 26 | — | 5.5% | ||
| Q4 25 | -2.9% | 7.7% | ||
| Q3 25 | -0.6% | 5.6% | ||
| Q2 25 | 6.4% | 6.4% | ||
| Q1 25 | -2.6% | 5.1% | ||
| Q4 24 | -3.8% | 10.3% | ||
| Q3 24 | -5.6% | 13.9% | ||
| Q2 24 | -3.6% | 5.7% |
每股收益（稀释后）ICUIPRG
| Q1 26 | — | $3.68 | ||
| Q4 25 | $-0.63 | $0.99 | ||
| Q3 25 | $-0.14 | $0.82 | ||
| Q2 25 | $1.43 | $0.95 | ||
| Q1 25 | $-0.63 | $0.83 | ||
| Q4 24 | $-0.97 | $1.33 | ||
| Q3 24 | $-1.35 | $1.94 | ||
| Q2 24 | $-0.88 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $69.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $774.4M |
| 总资产 | $4.1B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIPRG
| Q1 26 | — | $69.4M | ||
| Q4 25 | — | $308.8M | ||
| Q3 25 | — | $292.6M | ||
| Q2 25 | — | $222.0M | ||
| Q1 25 | — | $213.3M | ||
| Q4 24 | $308.6M | $90.9M | ||
| Q3 24 | $312.5M | $221.7M | ||
| Q2 24 | $302.6M | $250.1M |
总债务ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | — | $594.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $643.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ICUIPRG
| Q1 26 | — | $774.4M | ||
| Q4 25 | $2.1B | $746.4M | ||
| Q3 25 | $2.1B | $703.6M | ||
| Q2 25 | $2.1B | $668.7M | ||
| Q1 25 | $2.0B | $654.4M | ||
| Q4 24 | $2.0B | $650.3M | ||
| Q3 24 | $2.0B | $630.8M | ||
| Q2 24 | $2.0B | $581.9M |
总资产ICUIPRG
| Q1 26 | — | $2.0B | ||
| Q4 25 | $4.1B | $1.6B | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $4.1B | $1.5B | ||
| Q1 25 | $4.2B | $1.5B | ||
| Q4 24 | $4.2B | $1.5B | ||
| Q3 24 | $4.3B | $1.4B | ||
| Q2 24 | $4.3B | $1.5B |
负债/权益比ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $-54.9M | ||
| Q3 25 | $56.7M | $110.0M | ||
| Q2 25 | $11.2M | $69.9M | ||
| Q1 25 | $51.3M | $209.9M | ||
| Q4 24 | $40.2M | $-84.5M | ||
| Q3 24 | $36.1M | $31.9M | ||
| Q2 24 | $82.0M | $55.4M |
自由现金流ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $-57.5M | ||
| Q3 25 | $27.6M | $106.5M | ||
| Q2 25 | $-8.5M | $68.0M | ||
| Q1 25 | $36.7M | $208.0M | ||
| Q4 24 | $16.1M | $-86.8M | ||
| Q3 24 | $16.2M | $29.8M | ||
| Q2 24 | $62.5M | $53.5M |
自由现金流率ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | -10.9% | ||
| Q3 25 | 5.1% | 17.9% | ||
| Q2 25 | -1.5% | 11.2% | ||
| Q1 25 | 6.1% | 30.4% | ||
| Q4 24 | 2.6% | -15.5% | ||
| Q3 24 | 2.7% | 4.9% | ||
| Q2 24 | 10.5% | 9.0% |
资本支出强度ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 0.5% | ||
| Q3 25 | 5.4% | 0.6% | ||
| Q2 25 | 3.6% | 0.3% | ||
| Q1 25 | 2.4% | 0.3% | ||
| Q4 24 | 3.8% | 0.4% | ||
| Q3 24 | 3.4% | 0.3% | ||
| Q2 24 | 3.3% | 0.3% |
现金转化率ICUIPRG
| Q1 26 | — | — | ||
| Q4 25 | — | -1.36× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | 0.32× | 1.82× | ||
| Q1 25 | — | 6.05× | ||
| Q4 24 | — | -1.47× | ||
| Q3 24 | — | 0.38× | ||
| Q2 24 | — | 1.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PRG
暂无分部数据
